Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of liver disease worldwide, and its incidence continues to grow. Current research suggests that compositional and functional changes in gut microbiota can contribute to liver damage; however, the issue is complex and far from clear. To address this, the gut microbiome of 16 MASLD patients was compared with two control groups: 16 healthy individuals and 6 patients with chronic active hepatitis C (CAH-C) using 16S rRNA next-generation Illumina MiSeq sequencing. Alpha diversity of the intestinal microbiome was significantly lower in the MASLD group (p = 0.0328) when compared to the CAH-C group, whereas no significant difference was observed relative to healthy controls. Additionally, there was a negative correlation between phylogenetic diversity (PD) and fibrosis stage (p = 0.0506; Spearman r = −0.5129) within the MASLD cohort. Gut microbiome diversity was not associated with gender, basic clinical or biochemical parameters, BMI, or steatosis and only the fibrosis score correlated with microbiota composition. Nevertheless, distinct quantitative variations at multiple taxonomic levels emerged when comparing MASLD patients with healthy individuals. The MASLD cohort exhibited a significant enrichment of Prevotellaceae, Veillonellaceae (Dialister, Megasphaera), Rikenellaceae, and a notable depletion of Bifidobacteriaceae, Lactobacillaceae, Lachnospiraceae, Ruminococcaceae, and Enterobacteriaceae.